Quinolone Safety and Efficacy More Important than Potency

philus influenzae. Document no. WHO/CDS/CSR/EDC/99.7. Geneva: World Health Organization; 1999. 2. Cheesbrough M. Medical laboratory manual for tropical countries, Vol II. London: Butterworth-Heinemann; 1985. p.160–74. 3. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility testing. Approved standard, 7th ed. Document M2-A7. Wayne (PA): The Committee; 2000. 4. Uduman SA, Adeyemi E, El-Khadir A, Jose K, Benedict S, Bener A. Haemophilus influenzae type b still remains a leading cause of meningitis among unvaccinated children—a prospective CSF analysis study. J Trop Pediatr 2000;46:331–4. 5. Limcangco MR, Salole EG, Armour CL. Epidemiology of Haemophilus influenzae type b meningitis in Manila, Philippines, 1994 to 1996. Pediatr Infect Dis J 2000;19:7–11. 6. Lehmann D, Yeka W, Rongap T, Javati A, Saleu G, Clegg A, et al. Aetiology and clinical signs of bacterial meningitis in children admitted to Goroka Base Hospital, Papua New Guinea, 1989–1992. Ann Trop Paediatr 1999;19:21–32. 7. Sahai S, Mahadevan S, Srinivasan S, Kanungo R. Childhood bacterial meningitis in Pondicherry, South India. Indian J Pediatr 2001;68:839–41. 8. Migliani R, Clouzeau J, Decousser JW, Ravelomanana N, Rasamoelisoa J, Rabijaona H, et al. Non-tubercular bacterial meningitis in children in Antananarivo, Madagascar. Arch Pediatr 2002;9:892–7. 9. Matee MI, Matre R. Pathogenic isolates in meningitis patients in Dar Es Salaam, Tanzania. East Afr Med J 2001;78:458–60. 10. Dickinson FO, Perez AE, Galindo MA. Quintana I. Impact of vaccination against Haemophilus influenzae type b in Cuba. Rev Panam Salud Publica 2001;10:169–73. 11. Diaz JM, Catalan L, Urrutia MT, Prado V, Ledermann W, Mendoza C, et al. Trends of etiology of acute bacterial meningitis in Chilean children from 1989 to 1998. Impact of the anti-H. influenzae type b vaccine. Rev Med Chil 2001; 129:719–26. 12. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000;13:302–17.